We are live on !
Find out more
Column Group Portfolio holdings
AUM
$88.1M
Turnover
0%
1-Year Est. Return
148.03%
This Fund
S&P 500
This Quarter Est. Return
+43.57%
1 Year Est. Return
+148.03%
3 Year Est. Return
+95.12%
5 Year Est. Return
+23.89%
10 Year Est. Return
–
AUM
$161M
AUM Growth
+$9.16M
(+6.1%)
Cap. Flow
-$327K
Cap. Flow % of AUM
Cap. Flow %
-0.2%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
–
Reduced
2
Closed
–
Avg Time Held
2.6
years
Top 10 Avg Time Held
2.6
years
Top 20 Avg Time Held
2.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sagimet Biosciences
SGMT
|
+$123K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oric Pharmaceuticals
ORIC
|
+$325K |
| 2 |
Surrozen
SRZN
|
+$124K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Tenaya Therapeutics
TNYA
$79.6M
| $49.2M | 30.62% |
9,400,290
| – | – |
2021 Q3
10 quarters
|
|
|
2
Oric Pharmaceuticals
ORIC
$815M
| $48.7M | 30.33% |
3,540,777
-27,404
| -0.8% | -$325K |
2020 Q4
13 quarters
|
|
|
NGM
3
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $28.8M | 17.96% |
18,136,735
| – | – |
2020 Q4
13 quarters
|
|
4
DELISTED
RAPT Therapeutics
RAPT
| $24.1M | 14.99% |
335,078
| – | – |
2020 Q4
13 quarters
|
|
|
5
Surrozen
SRZN
$603M
| $9.7M | 6.03% |
616,540
-11,111
| -2% | -$124K |
2021 Q3
10 quarters
|
|
|
6
Sagimet Biosciences
SGMT
$735M
| $93.1K | 0.06% |
+17,169
| New | +$123K |
2024 Q1
0 quarters
|
|
7
Revolution Medicines
RVMD
$37.3B
| $1.48K | ﹤0.01% |
46
| – | – |
2020 Q4
13 quarters
|
|
Similar funds
KFP
HI
Column Group's Q1 2024 Portfolio in Review
As of Q1 2024, Column Group held 7 positions worth $161M, up 6.1% from $151M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Column Group's Q1 2024 filing shows 1 new and 2 reduced positions. Its largest new stake was Sagimet Biosciences: 17,169 shares worth $93.1K. The largest sale was Oric Pharmaceuticals, an estimated $325K.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Column Group's largest Q1 2024 buy was Sagimet Biosciences: 17,169 shares worth $93.1K.
- Column Group's biggest Q1 2024 reduction was Oric Pharmaceuticals, cutting an estimated $325K.
- Column Group's ten largest holdings make up 100% of its $161M portfolio in Q1 2024.
- Column Group opened 1 new position and closed 0 in Q1 2024.
- Column Group's portfolio value rose 6.1% quarter-over-quarter to $161M.
Based on Column Group's 13F filing for Q1 2024, filed 15 May 2024.